Hold Eliquis Temporarily, Then Resume at Reduced Dose
In a patient with DVT who has undergone surgery with small amounts of bleeding from nephrostomy drains, Eliquis (apixaban) should be held temporarily until adequate hemostasis is achieved, then resumed at a reduced dose (2.5 mg twice daily) for the first 2-3 days before returning to full therapeutic dosing.
Clinical Reasoning
This scenario represents a high bleeding risk surgery (urological procedure with nephrostomy tube placement) in a patient with high thrombotic risk (active DVT requiring anticoagulation). The presence of ongoing bleeding from drains, even if small, indicates that adequate surgical hemostasis has not yet been fully established.
Immediate Management
- Continue holding Eliquis while there is any active bleeding from the nephrostomy drains 1
- Monitor drain output closely - bleeding should be minimal to absent before restarting anticoagulation
- The FDA label specifies that apixaban should be restarted "as soon as adequate hemostasis has been established" 2
Resumption Strategy
Once bleeding has stopped or is truly minimal:
For high-risk thrombotic patients (which includes active DVT):
- Resume apixaban at 2.5 mg twice daily (reduced dose) for the first 2-3 days (48-72 hours postoperatively) 1
- After 2-3 days on reduced dose, increase to 5 mg twice daily (full therapeutic dose for DVT treatment) 1
- This graduated approach balances the competing risks of thrombosis versus bleeding
Timing considerations:
- For high bleeding risk procedures, guidelines recommend waiting 2-3 days (48-72 hours) before resuming full-dose anticoagulation 1, 3
- The reduced dose strategy allows earlier anticoagulation coverage while minimizing bleeding risk 1
Key Clinical Pitfalls
Do NOT:
- Resume full therapeutic dose (5 mg twice daily) immediately - this significantly increases bleeding risk in the early postoperative period
- Use bridging with parenteral anticoagulation (heparin/LMWH) - this is not recommended for DOAC interruption and increases bleeding complications 3
- Wait too long to restart anticoagulation in a patient with acute DVT - thrombotic risk is substantial
DO:
- Assess drain output objectively - document volume and character
- Consider surgical consultation if bleeding persists beyond 48-72 hours
- Monitor renal function, as this affects apixaban dosing and elimination 1, 3
- Ensure patient understands the dosing schedule change (reduced dose initially, then increase)
Evidence Strength
The graduated dosing approach is supported by Blood journal guidelines 1 and French GIHP guidelines 3, which specifically address high bleeding risk procedures. The 2022 CHEST guidelines 4 confirm that standardized DOAC interruption and resumption protocols result in low rates of both thrombotic events (0.16-0.60%) and major bleeding (0.9-1.85%).
The presence of active DVT makes this patient high thrombotic risk, necessitating anticoagulation resumption as soon as safely possible, but the ongoing bleeding mandates a cautious, graduated approach rather than immediate full-dose therapy.